Year: 2021

PHOENIX, Dec. 15, 2021 (GLOBE NEWSWIRE) — Leslie’s, Inc. (the “Company” or “Leslie’s”) (Nasdaq: LESL) today announced the pricing of an underwritten public offering of 12,500,000 shares of common stock (the “Offering”) by certain of the Company’s non-management stockholders (the “Selling Stockholders”). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock. The Selling Stockholders will receive all of the proceeds from the Offering. Leslie’s is not offering any shares of its common stock in the Offering and will not receive any proceeds from the Offering, including from any exercise by the underwriters of their option to purchase additional shares. Settlement is scheduled for December 16, 2021, subject to customary closing conditions. As previously...

The Company is working with its auditor to resolve the technical accounting related to non-cash items associated with the convertible notes issued during the second fiscal quarter Announces postponement of 10-Q filing and conference call scheduled for December 15, 2021, at 10:00 A.M. Eastern Time Reports record revenue of $5.4 million and year-over-year revenue growth of 106%BALTIMORE, Dec. 15, 2021 (GLOBE NEWSWIRE) — Slinger (OTCQB: SLBG), a leading connected sports technology company, today announced revenue and operating results for its second-quarter fiscal year 2021 ended October 31, 2021. The Company is working with its auditor to finalize the technical accounting for its convertible note brought up during the quarter-end close. Once there is a resolution, the Company will file its 10-Q and proceed with its earnings release...

Live Demonstration of the LIBERTY Robotic System is Planned for January 10th in San Francisco, CA HINGHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) achieved the design freeze objective for the LIBERTY® Robotic System. This milestone demonstrates the continued progress towards the commercialization of the world’s first fully disposable robotic system. The Company’s ability to reach this milestone within the previously stated timeframe reflects the tireless efforts of the Company’s engineering team, along with data compiled from the numerous feasibility animal studies and physician feedback. With the design freeze, in accordance with the Company’s previously provided timeline, the next meaningful milestone is the filing of the pre-submission with the U.S. Food and Drug Administration (FDA) during...

ROCHESTER, N.Y., Dec. 15, 2021 (GLOBE NEWSWIRE) — DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets, today announced the opening of a new office in Sacramento, California to serve as the home office for DSS Wealth Management Inc. (“DSS Wealth Management”) and DSS AmericaFirst Quantitative Funds (“DSS AmericaFirst”). “This is an exciting area of our business with significant rapid growth potential,” stated Jason Grady, COO of DSS. “Bringing the DSS Wealth Management and DSS AmericaFirst teams together in Sacramento should accelerate our sales and marketing initiatives while the ongoing expansion of our product portfolio with innovative quantitative...

TORONTO, Dec. 15, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in Citi’s Psychedelic Drug Call Series to be held virtually on Thursday, January 6, 2022.    Neena Bitritto-Garg, Citi’s Biotech analyst, will host James Lanthier, CEO of Mindset, and Joseph Araujo, CSO of Mindset, for a fireside chat at 10:00 a.m. ET. For more information about the event, please contact your appropriate Citi representative directly. Additionally, Mindset’s management team will be available to participate in investor and...

NORCROSS, Ga., Dec. 15, 2021 (GLOBE NEWSWIRE) — Intelligent Systems Corporation (NYSE: INS), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, announced today that it is changing its name to CoreCard Corporation. The Company anticipates its common stock will begin trading using new ticker symbol “CCRD” at the commencement of trading on December 29, 2021, and that its common stock will continue to trade on the NYSE under the symbol “INS” until the closing of trading on December 28, 2021. The Company’s corporate structure will not be changing, nor will its financial reporting. Leland Strange, CEO and Chairman, stated, “This change highlights our goal to grow our industry leading revolving credit platform as the primary business of the company. Intelligent...

Four in Five Believe Diversity in Clinical Trials Will Be as Important as Safety and Efficacy WASHINGTON, Dec. 15, 2021 (GLOBE NEWSWIRE) — FTI Consulting (NYSE: FCN) today announced a new survey and report, U.S. Healthcare & Life Sciences Industry Outlook 2022, that found nearly three-quarters (71%) of U.S. healthcare and life sciences executives believe trustworthiness is the most important characteristic in the next Federal Drug Administration (“FDA”) commissioner, significantly ahead of deep scientific knowledge (48%), leadership (46%) and innovation (45%). The survey also found that 82% of respondents are confident that diversity will be equally as important as demonstrating safety and efficacy in clinical trials within the next 12 months. FTI Consulting’s Strategic Communications segment surveyed more than 250 decision...

— Vanderbilt University Medical Center patient received the HAV under the U.S. Food and Drug Administration’s (FDA) Expanded Access Program (EAP) in April 2019 — — After replacement, the patient resumed regular physical activity with no signs of infection of the HAV implant observed — — Published in Journal of Vascular Surgery: Cases, Innovations and Techniques — — HAV used in 20 EAP cases to date, for treatment of severe vascular disease and trauma — DURHAM, N.C., Dec. 15, 2021 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that results from a case study of a patient who received the human acellular vessel (HAV) as a replacement for...

Figure 1: Plan View of the Copper World ProjectThe Copper World project consists of seven mineral deposits hosting both oxides and sulphide copper mineralization at shallow depths over a seven-kilometre strike area, with a majority of the deposits located on private mining claims adjacent to Rosemont.Figure 2: Location of Deposits in Proximity to the Backbone FaultSignificant oxide mineralization located along a regional fault that runs near the west side of the Rosemont, Bolsa and Broad Top Butte deposits known as the Backbone Fault.Figure 3: Higher Grade Portion Expected to be Mined EarlierLongitudinal section showing Bolsa, Copper World, Peach-Elgin and Broad Top Butte pit shells with higher grade mineralization located closer to surface and expected to be mined earlier in the mine life.Figure...

SAN DIEGO, Dec. 15, 2021 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“Salona” or the “Company”) (TSXV:SGMD), an acquisition-oriented medical device company serving the global injury and surgery recovery (known as recovery science) market, has posted a recording of last week’s investor call on its website. The recording can be accessed at https://www.salonaglobal.com/downloads. For more information please contact: Les CrossChairman of the Board and Interim Chief Executive OfficerTel: 1 (800) 760-6826Email: Info@Salonaglobal.com Additional Information There can be no assurance that any acquisitions mentioned on the investor call will ‎be completed or the timing of any acquisitions. Completion of any transaction will be subject to ‎applicable ‎director, shareholder ‎and regulatory approvals.‎ Neither the TSXV nor...